Researchers launch 1 million-record dog and cat tumor database

CURRENT FULL VERSION: Researchers in the UK and Spain have launched what they describe as the world’s largest open-source database of dog and cat tumors, a milestone that could give veterinary oncology a much stronger evidence base for studying cancer risk across breeds, species, and tumor types. The database, created by the University of Liverpool’s Veterinary Data Science Group and the University of Las Palmas de Gran Canaria, contains more than 1 million records and is intended to let researchers interrogate patterns that smaller, fragmented datasets often miss. (liverpool.ac.uk)

The announcement is the latest step in a longer registry-building effort centered on SAVSNET, Liverpool’s Small Animal Veterinary Surveillance Network. In 2021, many of the same investigators published an open-access data descriptor in Scientific Data covering 100,000 canine and feline tumors in the UK, using text mining to turn electronic pathology records into a usable tumor registry. That earlier paper highlighted both the promise and the challenge of veterinary cancer surveillance: large volumes of pathology data exist, but they’re often siloed, inconsistently coded, and difficult to analyze at scale. (nature.com)

According to the University of Liverpool, the new resource was built by unifying those large pathology datasets into a “meaningful, research-ready database.” The stated goal is to help researchers worldwide study cancer risk across tumor-breed combinations, including rare cancers and less common breeds that are easy to overlook in smaller registries. The university said the work is being done in collaboration with diagnostic laboratories participating in the network, including BattLab, and that one dog-focused component of the project is already reflected in a newly published Veterinary and Comparative Oncology paper on four major canine tumors in the UK. (liverpool.ac.uk)

That scale matters because veterinary oncology has historically had fewer population-level registries than human oncology. Older efforts, including registries in Denmark, Italy, California, and Portugal, have shown the value of structured cancer surveillance for identifying common malignancies and breed predispositions, but they’ve generally been much smaller or geographically narrower. The new database appears positioned less as a local registry and more as a shared infrastructure layer for future epidemiology and comparative oncology studies. That’s especially relevant as the field increasingly links spontaneous cancers in dogs and cats with human oncology research. (bmcvetres.biomedcentral.com)

Direct outside commentary on this specific launch was limited, but broader expert discussion in comparative oncology points in the same direction. AVMA has previously highlighted the National Cancer Institute-backed Canine Comparative Oncology and Genomics Consortium as an example of how naturally occurring cancers in pets can inform translational research. More recently, that case has been strengthened on the feline side by a large Science study that sequenced 493 tumor-normal pairs from cats across five countries and 13 cancer types, creating what researchers described as the first large-scale map of the feline oncogenome. Across those tumors, TP53 was the most frequently mutated gene, appearing in roughly a third of cases, and investigators also identified recurrent driver alterations in genes such as FBXW7, CTNNB1, PTEN, and TRAF3. In mammary carcinoma, one of the most common and aggressive feline cancers, FBXW7 mutations were found in more than half of tumors and PIK3CA alterations in nearly half, with laboratory testing suggesting FBXW7-mutant tumors may show greater sensitivity to some chemotherapy agents. Those findings are early and not the same as clinical efficacy, but they underscore why large, well-structured animal cancer datasets are increasingly seen as useful foundations for precision oncology and cross-species discovery. (avma.org)

That translational arc is not limited to genomics. In canine lymphoma, for example, a recent Scientific Reports study in pet dogs with diffuse large B-cell lymphoma found that immune-gene signatures in serial blood samples were associated with treatment response and survival under newer chemo-immunotherapy regimens. The work points toward a more practical “liquid biopsy” model in which blood-based markers could eventually help identify poor responders earlier and guide treatment selection in both veterinary and human oncology. A large pathology registry will not provide that kind of biomarker signal on its own, but it can help define which populations, tumor types, and clinical questions are worth pursuing in prospective studies. (newswise.com)

For practicing veterinarians, some of the value of better surveillance is also in making uncommon presentations more visible. A recent long-term institutional cohort of male dogs and cats with mammary tumors, for instance, found those tumors were predominantly malignant in both species, with cats skewing toward intermediate- and high-grade disease. In that series, caudal mammary glands were most commonly affected, complex carcinoma was the most common diagnosis in male dogs, and tubular carcinoma in male cats. Findings like that are exactly the kind of niche but clinically useful signal that larger registries may be able to surface more consistently across institutions and populations. (wiley.com)

Why it matters: For practicing veterinarians, the immediate value is less about a new bedside tool and more about better evidence. Large registries can improve understanding of age, breed, sex, and tumor-site associations, help benchmark what clinicians are seeing in practice, and support earlier recognition of patterns that may warrant referral, screening discussions, or client education. For specialists and researchers, the database could make it easier to study uncommon cancers, validate suspected predispositions, and generate the kind of large-cohort evidence needed for precision oncology and trial design. The recent feline genomics work adds a concrete example of where that could lead: researchers found that 14% of feline tumors carried an oncogenic or likely oncogenic alteration considered potentially actionable, suggesting at least some future path toward mutation-guided treatment rather than species- or site-based treatment alone. (nature.com)

The registry also lands at a moment when veterinary cancer research is becoming more data-driven. Recent work in dogs and cats has focused on genomic profiling, immune signatures, and comparative models that mirror human disease biology. A large, open-source pathology database won’t answer all of those questions on its own, but it can provide the epidemiologic backbone for deciding which tumors, breeds, and populations deserve deeper molecular study. In cats, that now includes tumor types such as cutaneous squamous cell carcinoma, lung adenocarcinoma, lymphoma, and mammary carcinoma that featured prominently in the new oncogenome map, as well as specific signals such as frequent MYC copy-number gain in T-cell lymphoma and heavy copy-number disruption in mammary carcinoma. (veterinaryoncology.biomedcentral.com)

What to watch: The next key marker will be publication of peer-reviewed analyses derived from the registry, especially studies that quantify breed-specific risk, tumor incidence patterns, or referral-relevant trends, and any move to connect this pathology resource with genomic or clinical-outcome datasets. If that happens, the database could become more than a catalog of diagnoses: it could become the organizing layer that helps link routine pathology, molecular profiling, and treatment-response research across veterinary oncology. (miragenews.com)